Abstract 46P
Background
ABCB1 gene reported to affect chemo-induced toxicity through drug disposition and efflux mechanisms. This study aims to evaluate the influence of ABCB1 (C1236T, G2677T/A, C3435T) polymorphisms on, chemotoxicity, and survival outcomes in BC patients treated with anthracycline and taxane either sequentially or concomitantly.
Methods
100 patients were included who received sequential or concomitant anthracycline and taxane as per clinician discretion and underwent modified radical mastectomy. Chemotoxicity grade was analyzed by CTCAE v.4. All patients received standard premedication with 5HT3, NK1 receptor antagonist, dexamethasone, H2 blocker/ PPI. SNP of ABCB1 (C1236T, G2677T/A, C3435T) gene was detected by PCR-RFLP and sequencing.
Results
Patients mostly reported at Stage III (52.89%) with infiltrating ductal carcinoma subtype (90.9%) who received sequential (50%) & concomitant (50%) chemotherapy. Grade ≥2 chemo toxicity like neutropenic fever, significantly associated with C1236T SNP with odd ratio (OR) for TT genotypes was 2.00 (95% CI: 0.125-31.975, p=0.000), while in CT genotypes, it stood at 1.100 (95% CI: 0.063-15.988; p = 0.035). Meanwhile, vomiting was significantly associated with C3435T for TT genotypes, with an OR of 3.031 (95% CI: 0.031-7.994, p=0.05). TT genotypes (C1236T) were significantly associated with nausea (OR: 2.667; 95% CI: 1.043-6.815; p = 0.04). Alopecia was observed 88% patients. However, ABCB1 showed no significant (p = 0.416, Log-rank) correlation for overall survival. Although, no significant associations were found for G2677T/A in terms of toxicity and survival.
Conclusions
The homozygous mutant TT genotypes (C1236T and C3435T) and heterozygous CT genotypes (C1236T) showed significant association to chemo-induced toxicity (hematological toxicity, nausea, vomiting, alopecia) in patients underwent anthracycline and taxane. Hence, these SNPs could serve as predictive markers to mitigate chemotherapy's adverse effects and optimize treatment to reduce the grade of toxicity and improves patients quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
V. D. Nasare.
Funding
This work is funded by Council of Scientific and Industrial Research, Government of India, File No. 09/030(0085)/2019-EMR-I awarded to Tanuma Mistry.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract